CAMBRIDGE, Mass., March 28, 2026
Anumana, an AI-driven cardiovascular health technology company, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its first-of-its-kind ECG-AI algorithm designed to detect pulmonary hypertension (PH) at an early stage, marking a major advancement in AI-powered diagnostics and digital health innovation. The algorithm, a software-as-a-medical-device (SaMD), integrates with standard 12-lead electrocardiograms (ECGs), enabling clinicians to identify early disease signals and improve patient outcomes through timely intervention and enhanced clinical decision-making.
AI Innovation Enables Early Detection of Pulmonary Hypertension
The newly cleared ECG-AI pulmonary hypertension algorithm represents a significant breakthrough as the first FDA-cleared solution capable of detecting PH using routine ECG data, making advanced diagnostics widely accessible across healthcare settings. Pulmonary hypertension is a serious, progressive condition affecting the lungs and right side of the heart, often associated with delayed diagnosis due to non-specific symptoms such as shortness of breath, leading to increased morbidity and mortality.
By leveraging advanced artificial intelligence and machine learning, the algorithm detects subtle physiological patterns that may not be visible to clinicians, enabling earlier identification of at-risk patients. This allows healthcare providers to initiate timely follow-up testing, such as echocardiography, significantly improving the chances of early intervention and better clinical outcomes.
Importantly, the solution integrates seamlessly into existing clinical workflows and ECG systems, ensuring that healthcare providers can adopt the technology without requiring major infrastructure changes, thereby accelerating real-world implementation and scalability.
Advertisement
Robust Clinical Validation Demonstrates Strong Performance
The FDA clearance is supported by extensive clinical development and validation, including training on more than 250,000 de-identified patient records and evaluation across multiple healthcare systems. In a multi-center study involving over 21,000 patients, the algorithm demonstrated 73% sensitivity and 74.4% specificity in detecting pulmonary hypertension among symptomatic individuals.
Further real-world analyses showed that the AI model successfully identified over 85% of patients with pulmonary arterial hypertension (PAH) and 78% of patients with chronic thromboembolic pulmonary hypertension (CTEPH) prior to formal diagnosis. These findings highlight the algorithm’s ability to detect disease earlier in its progression, providing a critical window for clinical intervention and improved patient management.
Additionally, the system operates entirely within healthcare environments and integrates with electronic health record (EHR) systems, ensuring data privacy, security, and compliance with regulatory standards, which are essential for adoption in modern healthcare ecosystems.
Advancing Digital Health and Cardiovascular Care
The clearance of Anumana’s ECG-AI algorithm reflects the growing impact of artificial intelligence in transforming cardiovascular diagnostics, particularly in enabling early disease detection and predictive healthcare models. By enhancing the capabilities of routine ECGs, the technology transforms a widely available diagnostic tool into a powerful predictive platform for identifying cardiovascular risk at scale.
With pulmonary hypertension affecting up to 1% of the global population, early detection remains a critical challenge. Anumana’s solution addresses this gap by providing clinicians with real-time, AI-driven insights at the point of care, supporting faster diagnosis and more informed treatment decisions.
The company’s broader strategy focuses on expanding the role of AI across the continuum of care, including diagnostic, predictive, and intraoperative applications. This milestone further strengthens Anumana’s position as a leader in AI-enabled healthcare solutions, driving innovation that improves both clinical efficiency and patient outcomes.
The FDA clearance of Anumana’s ECG-AI pulmonary hypertension algorithm represents a transformative step in AI-driven medical diagnostics, enabling earlier detection of a life-threatening condition through routine ECG analysis. With strong clinical validation, seamless integration into healthcare systems, and the potential to significantly improve patient outcomes, this innovation highlights the growing role of MedTech and artificial intelligence in shaping the future of healthcare delivery.
Source: Anumana press release
